Toronto, Ontario – January 29, 2007
- Novadaq® Technologies Inc. (TSX: NDQ), a developer of medical imaging
systems for the operating room, and Apple Inc. held a two-hour evening
event, “Join the Imaging Revolution”, on Sunday, January 28, 2007 at
Jimmy Love’s in San Diego, California, for an estimated 100 heart
surgeons from around the world. These surgeons are among the more than
2,000 attendees to the Society of Thoracic Surgeons 43rd Annual Meeting
being held at the San Diego Convention Center, through January 31.
Novadaq showcased its SPY® Intra-operative Imaging System, a real-time
visual imaging device for use during heart bypass surgery.
Additionally, Apple shared how its technologies are being used in
medicine and how the iPod is facilitating personal and portable medical
media.
"We are delighted that Apple co-sponsored this event with Novadaq,”
said Dr. Arun Menawat, President and Chief Executive Officer Novadaq
Technologies Inc. "Novadaq’s innovations are providing medical imaging
for the operating room to improve clinical outcomes and Apple is the
leader of innovation in the personal computing industry. It’s a
synergistic fit between technologies and a perfect opportunity for
cardiac surgeons to see and participate in the imaging revolution.”
Speakers presented on how new technology is helping doctors use imaging
in new ways to help patients and educated cardiac surgeons about Apple
technology in medicine.
The SPY System is the first, and only fluorescent imaging system
cleared by the U. S. Food and Drug Administration for use in coronary
artery bypass surgery, the most common open-heart surgery in the
country with approximately 400,000 patients undergoing the procedure
every year. Bypass surgery is one of the only major vascular surgeries
in which imaging is not yet a standard of care.
SPY enables cardiac surgeons to simply and efficiently assess the
quality of blood flow through the heart during surgery. Use of the SPY
System may reduce complications, and help patients avoid repeat heart
procedures.
About Apple Inc.
Apple ignited the personal computer revolution in the 1970s with the
Apple II and reinvented the personal computer in the 1980s with the
Macintosh. Today, Apple continues to lead the industry in innovation
with its award-winning desktop and notebook computers, OS X operating
system, and iLife and professional applications. Apple is also
spearheading the digital music revolution with its iPod portable music
players and iTunes online store.
About Novadaq Technologies
Novadaq Technologies Inc. (TSX: NDQ) develops and commercializes
medical imaging devices for use in the operating room. Novadaq’s
proprietary imaging platform can be used to visualize blood vessels,
nerves and the lymphatic system during surgical procedures. Novadaq’s
SPY Intra-operative Imaging System, commercially available worldwide,
enables cardiac surgeons to visually assess coronary vasculature and
bypass graft functionality during the course of open-heart surgery.
Novadaq’s OPTTX® System which received CE Mark approval in November
2006, is aimed at the diagnosis, evaluation and treatment of wet
Age-related Macular Degeneration (AMD) by using the same core imaging
technology that is used in the SPY System. The HELIOS™ System, which
received FDA clearance in January 2007, is the first fluorescent
imaging system available for use during plastic reconstructive surgery
allowing surgeons to evaluate pre- and intra-operative blood flow, as
well as post-surgery perfusion. Novadaq’s LUNA™ system is designed to
enable surgeons to visualize nerve bundles during the course of
urological and neurological procedures. LUNA™ has been granted a
license for use by Health Canada. For more information, please visit
the company's website at www.novadaq.com.
Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those
implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. All
forward-looking statements are based on Novadaq's current beliefs as
well as assumptions made by and information currently available to
Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments,
market acceptance and future commitments. Readers are cautioned not to
place undue reliance on these forward-looking statements, which speak
only as of the date of this press release. Due to risks and
uncertainties, including the risks and uncertainties identified by
Novadaq in its public securities filings; actual events may differ
materially from current expectations. Novadaq disclaims any intention
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
For further information visit our website at www.novadaq.com, or contact:
Arun Menawat, PhD, MBA
President & CEO
Novadaq Technologies Inc.
Phone: 905-629-3822 x 202
amenawat@novadaq.com
Investor Relations:
Michael Moore
The Equicom Group
Phone: 416-815-0700 x 241
mmoore@equicomgroup.com
